PharmaLegacy Laboratories (Shanghai) Co., Ltd was founded in 10 years ago, After a period of rapid development, it has developed into a considerable size and effectiveness company of PDX ModelandSyngeneic mouse model, NOw it is benchmark companies in 商务服务,医疗服务,医疗保健 industry.

   Innovation is the cornerstones of PharmaLegacy Laboratories (Shanghai) Co., Ltds success. In the future, PharmaLegacy also hope to continue to innovate, for the majority of customers to provide Syngeneic mouse modelservice. Over the years, PharmaLegacy always believe that only adhere to innovation and professional, in order to better meet customer demand for High-quality CDX Model. details:Cell line-Derived Xenograft (CDX model) is a well-established and commonly used mouse tumor model type for the research and development of anti-tumor drugs and immunotherapy. More recently, human tumors implanted directly into immunodeficient mice have become increasingly popular as evidence accrues that they more accurately recapitulate features of patient tumors. However, CDX model still possesses pervasive application at the early stage of in vivo study, due to its user-friendly techniques as well as excellent repeatability.With decades of operational experience and technology platform of tumor cells, Pharmalegacy has established various well-validated cell-line-derived xenograft (CDX model) to satisfy your in vivo research, of which both solid tumors and precious hematological malignances models are available to customers. Our all-around products involve CDX model construction and delivery, in vivo projects execution as well as the final results presentation in the field of Oncology research.

   Adhering to the "Customer Supreme Forge Ahead" management idea, PharmaLegacy insists on providing the best quality and service of Syngeneic mouse model,Rheumatoid arthritis Modelx2a38631n with the "customer first" principle. Wholeheartedly welcome your patronage! Official website address: www.pharmalegacy.com

PharmaLegacy Laboratories is a leading speciality pharmacology Contract Research Organization located in Shanghai Zhangjiang High-Tech Park, China. PharmaLegacy is equipped with a world-class facility, working to international pharmaceutical industrial standards. PharmaLegacy provides preclinical in vivo pharmacology efficacy services as well a therapeutic antibody discovery service program. Our state-of-the-art platforms include:· Pioneering work using CD34+ humanized mice that carry a human immune system, to test biologics for immuno-oncology therapeutic efficacy· An NHP platform for therapeutic biologics testing in a variety of immune diseases · An advanced antibody discovery platform based on single B cell antibody sequencing · An internationally recognized Bone/Orthopaedics platform to test both hard tissue disease therapeutic candidates and medical devicesPharmaLegacy offers a full range of preclinical pharmacology services for evaluating pharmacological effects of drug candidates in the areas of inflammation/auto-Immune diseases, lung injury, liver/metabolic diseases and oncology. Our NHP platform and CD34+ humanized mice models have helped dozens of clients with IND filings